Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Q4 2024 Earnings Call Transcript February 10, 2025 Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and ...

In addition to the launch of Niktimvo, the sNDA for ruxolitinib cream in pediatric atopic dermatitis ... driven by growth in AD and vitiligo new patients and refills, and $24 million ex-US, driven by ...

Jakafi ® (ruxolitinib) net revenues of $773 million (+11% Y/Y ... Net product revenues were primarily driven by patient ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Q4 2024 total revenues reached $1.2 billion, with $1 billion in product revenues. Jakafi's Q4 net revenue increased 11% year-over-year to $773 million, while Opzelura's Q4 revenue grew 48% to $162 ...

Vitiligo is a complex autoimmune condition in which the body ... Current treatments, including the FDA-approved Opzelura (ruxolitinib) cream, have limitations, with only 30% of patients experiencing ...

Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can re-pigment skin in vitiligo ahead of a key FDA decision in atopic dermatitis.

In 2022, the FDA approved the first re-pigmentation therapy for vitiligo: Opzelura (ruxolitinib) cream. Clinical trials found that only 30% of patients using the cream regained 75% or more skin ...

In 2022, the FDA approved the first re-pigmentation therapy for vitiligo: Opzelura (ruxolitinib) cream. Clinical trials found that only 30% of patients using the cream regained 75% or more skin re ...